This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Optimum Platelet Inhibition After Coronary Bypass Surgery

This study has been completed.
Information provided by (Responsible Party):
Papworth Hospital NHS Foundation Trust Identifier:
First received: December 5, 2005
Last updated: January 21, 2016
Last verified: January 2016
To investigate the effect of different dosages of aspirin on platelet aggregation and to determine the possible mechanisms of aspirin resistance, we intend to compare the effects of low, medium dose aspirin with clopidogrel (an alternative antiplatelet agent) in patients after coronary artery bypass surgery.

Condition Intervention
Ischemic Heart Disease Drug: Aspirin, Clopidogrel

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Optimum Platelet Inhibition After Coronary Artery Bypass Surgery: A Randomised Trial Comparing Platelet Aggregation Using Low, Medium Dose Aspirin and Clopidogrel

Resource links provided by NLM:

Further study details as provided by Papworth Hospital NHS Foundation Trust:

Study Start Date: July 2002
Primary Completion Date: July 2004 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

We intend to invite patients aged 18 to 80 proceeding to primary elective coronary artery bypass surgery, able to give informed consent.

Exclusion Criteria:

Preoperative exclusion criteria:

  • patients who are have not stopped aspirin 7 days prior to surgery
  • patients on concomitant NSAIDS
  • patients with a previous history platelet disorders, splenectomy or haematological disorders
  • patients with aspirin induced asthma
  • patients with any contraindications to aspirin (GI bleed)
  • patients who are on any medication that may result in a serious drug interaction with aspirin (warfarin)
  • Women of childbearing potential
  • Patients of less than 18 years
  • If informed consent cannot be obtained
  • If for any reason the consultant surgeon or anaesthetist deems it to be appropriate

Operative exclusion criteria:

• Concomitant procedures

Postoperative exclusion criteria:

  • patients who receive platelet transfusion
  • patients who receive NSAIDS
  • requirement for intra aortic balloon pump support
  • failure of extubation within 24 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262275

United Kingdom
Papworth Hospital
Cambridge, United Kingdom, CB3 8RE
Sponsors and Collaborators
Papworth Hospital NHS Foundation Trust
Principal Investigator: Eric Lim, MB ChB, MSc, MRCS Papworth Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Papworth Hospital NHS Foundation Trust Identifier: NCT00262275     History of Changes
Other Study ID Numbers: LREC 01/624
Study First Received: December 5, 2005
Last Updated: January 21, 2016

Additional relevant MeSH terms:
Heart Diseases
Myocardial Ischemia
Coronary Artery Disease
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arterial Occlusive Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on June 23, 2017